Research programme: synthetic humanised camelid nanobodies - Curie Institute/THERAVECTYS

Drug Profile

Research programme: synthetic humanised camelid nanobodies - Curie Institute/THERAVECTYS

Alternative Names: Synthetic humanised camelid single-domain antibodies - Curie Institute/THERAVECTYS

Latest Information Update: 20 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Curie Institute
  • Developer Curie Institute; THERAVECTYS
  • Class Immunotherapies; Single-domain antibodies
  • Mechanism of Action CD27 antigen inhibitors; Checkpoint kinase inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 14 Apr 2015 Synthetic humanised camelid nanobodies licensed to THERAVECTYS worldwide
  • 14 Apr 2015 Early research in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top